Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
BioAtla, Inc. - Common Stock
(NQ:
BCAB
)
0.6410
+0.0210 (+3.39%)
Streaming Delayed Price
Updated: 11:21 AM EST, Dec 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about BioAtla, Inc. - Common Stock
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
September 23, 2024
From
Context Therapeutics Inc.
Via
GlobeNewswire
BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
December 20, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event
December 05, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla to Participate in the JMP Securities Hematology and Oncology Summit
November 30, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC
November 28, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress
November 07, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla to Participate in the Jefferies London Healthcare Conference
November 06, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla’s Jay M. Short, Ph.D., Selected for The Explorers Club Lowell Thomas Award
October 12, 2023
Award recognizes Dr. Short’s contribution to science innovation
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023
October 10, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla to Participate in Upcoming Investor Conferences in August
August 03, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla Reports Second Quarter 2023 Financial Results and Highlights Recent Progress
August 01, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023
July 25, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index
June 26, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla to Participate in the Jefferies Healthcare Conference
May 31, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress
May 11, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla to Participate in the JMP Securities Life Sciences Conference
May 08, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023
May 04, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress
March 23, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla to Announce Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Highlights
March 16, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla Announces Change in Executive Leadership
February 27, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma
February 23, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones
January 10, 2023
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla to Participate in the 41st Annual J.P. Morgan Healthcare Conference
December 22, 2022
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla to Participate in the Jefferies London Healthcare Conference
November 08, 2022
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla Announces $65 Million Underwritten Offering of its Common Stock
November 04, 2022
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
November 03, 2022
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022
October 27, 2022
From
BioAtla, Inc.
Via
GlobeNewswire
BioAtla to Announce Second Quarter 2022 Financial Results and Provide Business Highlights on August 9, 2022
August 02, 2022
From
BioAtla, Inc.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.